Protective Role Of The Depressor Arm Of The Renin-angiotensin System During Pregnancy
Funder
National Health and Medical Research Council
Funding Amount
$633,384.00
Summary
The motivation for unveiling the normal hormonal and molecular mechanisms involved in the extraordinary vasodilatation associated with pregnancy is that understanding these fundamental processes may provide novel insights into the pathophysiology of preeclampsia and intrauterine growth restriction, as well as potential therapeutic strategies for not only the treatment of these pregnancy specific conditions but also cardiovascular and renal diseases in non-pregnant women and men.
In Vivo Studies On Ventriculo-vascular Coupling And The Role Of Aortic Pressure Wave Morphology On Coronary Blood Flow
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Heart disease is a leading cause of death and disability in Australia. Conditions resulting in reduced blood flow to the heart are particularly common and dangerous. Despite significant progress, we still do not understand exactly how changes in heart function and the aorta (the major artery arising from the heart) affect blood flow to the heart. This study will utilise sophisticated new techniques to look at the interactions between heart function, pressure in the aorta and coronary blood flow
UTILITY OF NOVEL BIOMARKERS IN THE PREDICTION OF MAJOR COMPLICATIONS OF TYPE II DIABETES MELLITUS
Funder
National Health and Medical Research Council
Funding Amount
$510,639.00
Summary
Diabetes is increasingly common. It can cause a variety of complications, the most serious being heart and kidney disease. The reasons why some patients develop such complications are not fully understood so it is difficult to predict who will be affected. The current project will use samples from a large international study of patients with diabetes to assess whether levels of specific markers in the blood help to predict major complications and clarify why they occur.
The L-type Calcium Channel As A Reporter Of Successful Morpholino Oligomer Therapy In Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy
Funder
National Health and Medical Research Council
Funding Amount
$595,062.00
Summary
Duchenne Muscular Dystrophy is a fatal muscle wasting disorder. We have previously characterised how the heart fails in a mouse model of muscular dystrophy. We now have preliminary data demonstrating that treatment of mice with morpholino oligomers can rescue cardiac function. This project will fully characterise the effect of the treatment on heart function and optimise therapy regimes with the view to utilising the optimised protocol as a guideline in treating cardiomyopathy in Duchenne Muscul ....Duchenne Muscular Dystrophy is a fatal muscle wasting disorder. We have previously characterised how the heart fails in a mouse model of muscular dystrophy. We now have preliminary data demonstrating that treatment of mice with morpholino oligomers can rescue cardiac function. This project will fully characterise the effect of the treatment on heart function and optimise therapy regimes with the view to utilising the optimised protocol as a guideline in treating cardiomyopathy in Duchenne Muscular Dystrophy boys.Read moreRead less
New Insights Into The Mechanisms Of Thrombogenesis In Atrial Fibrillation
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Atrial fibrillation (AF) is the most common heart rhythm disturbance (arrhythmia), which is associated with a high risk of stroke due to clot formation within the left atria. At present we still only have a limited understanding of the mechanism of clot formation in AF. The aim of this study is to determine the critical mechanisms that contribute to clot formation within the left atria in AF. This knowledge is fundamental to the development of more successful interventional approaches.
A Novel Therapy For The Prevention And Treatment Of Familial Hypertrophic Cardiomyopathy
Funder
National Health and Medical Research Council
Funding Amount
$835,972.00
Summary
Familial hypertrophic cardiomyopathy is a genetic disorder that leads to enlargement of the heart, cardiac failure and sudden death. No treatment exists that can reverse or prevent the cardiomyopathy. In this proposal we will determine whether a peptide (Patent WO2013/113060) targeting a calcium channel can prevent or reverse the cardiomyopathy as a novel treatment for the disease.
Targeting A New Regulator Of Cardiac Pathology To Protect The Heart From Cardiac Dysfunction And Arrhythmia
Funder
National Health and Medical Research Council
Funding Amount
$717,857.00
Summary
Heart failure is associated with high mortality, and treatment of this condition represents a major unmet need. We recently reported that specific lipid species are elevated in hearts of mice with heart failure. The goal of this study is to comprehensively examine the therapeutic potential of targeting these lipid species with drugs.